The 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease

Project: Research project

Project Details

Description

Compelling genetic, biochemical, cell biological, animal model, and human studies suggest that cerebral accumulation of the -amyloid peptide (A) has a critical early role in Alzheimer’s disease (AD) pathogenesis. The -secretase enzyme BACE1 is the rate-limiting enzyme for A production. Thus, BACE1 is a prime therapeutic target for the treatment or prevention of AD. Several BACE1 inhibitor drugs for AD are in clinical trials, but the safety and efficacy of these agents are unknown. The BACE proteases field comprises very active and diverse areas of research that have high impact on therapeutic approaches to treat and prevent AD. Here, I propose the 2nd Kloster Seeon Meeting on BACE Proteases in Health and Disease, September 25-27, 2016, in Bavaria, Germany, which has the following objectives: 1) disseminate the latest information on BACE proteases research and catalyze discussion among scientists in academia and industry, 2) promote the training of young scientists, and 3) publish a state-of-the-art review of BACE research to help advance the field and facilitate the development of safe and effective BACE inhibitor drugs for AD. The Scientific Program consists of: 1) a Keynote Lecture by Dr. Kari Stefansson (DeCode Genetics), who recently discovered a mutation in APP that protects against AD by reducing BACE1 cleavage, thus providing proof of concept for therapeutic BACE1 inhibition, 2) two full days of sessions comprising 25-minute talks from 24 leading experts in the BACE proteases field, 3) a session of 2-minute flash talks given by 10 selected graduate students and post-doctoral researchers to introduce their posters, 4) poster sessions on each of two evenings that will enhance the training experience of students and post-docs, 5) a panel discussion between academic and industry scientists on the current state of BACE research and drug development, 6) a conclusion and summary session to remark on the meeting and discuss the direction forward for the
StatusFinished
Effective start/end date9/25/169/24/17

Funding

  • Eli Lilly and Company (Agmt 8/31/16)

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.